Demonstrates Commitment to Be Near BioPharmaceutical Customers While Being Premier Geographically-Focused Provider of Clinical Research Services in Russia and Eastern Europe
SAN FRANCISCO, July 19, 2011 /PRNewswire/ -- ClinStar, LLC, an established CRO providing clinical research services in the emerging markets of Russia and Eastern Europe to the pharmaceutical and biotechnology industry, announced today the opening of a new regional office on the East Coast of the United States.
(Photo: http://photos.prnewswire.com/prnh/20110719/SF36975LOGO)
As a second US location to its headquarters in San Francisco, CA, ClinStar's new office is located at 1000 Park Forty Plaza, Durham, NC. In addition to offering adequate space to centralize ClinStar's regional workforce, the new facility was chosen in large part because of its flexibility to accommodate the company's future growth.
According to President and CEO David Passov, "This is the realization of a major long-term business goal for ClinStar. Our new office further solidifies our commitment to offer our clients the local expertise and knowledge they need to successfully conduct clinical trials in Russia and Eastern Europe while ensuring our business operates in accordance with the proven business and management principles practiced in the West."
"We are thrilled with the opening of our new office," says Erin King, Executive Director Business Development and Marketing. This move is just one of several important initiatives positioning ClinStar as the leading provider of clinical research services in Russia, Ukraine and parts of Eastern Europe. Our new facility affords not only centralized office space for our employees, but also upscale conference space for hosting meetings with our customers."
About ClinStar, LLC
ClinStar is one of the most prominent CROs in the emerging markets of Eastern Europe and the Baltics, with more than 10 years of expertise in Phase I-IV clinical studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus with total staff of over 300 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at www.clinstar.com.
SOURCE ClinStar, LLC